Blood Flow MRI for Monitoring Brain Tumors (Glioma)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538264|
Recruitment Status : Active, not recruiting
First Posted : February 24, 2012
Last Update Posted : February 26, 2019
|Condition or disease|
Our goals are:
- To compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. This will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors.
- To compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. This choline concentration can be measured with another MRI technique. This information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary.
- To determine the reproducibility of blood flow measurements in tumors. This is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity.
- To monitor changes in blood flow after initial treatment. Since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.
|Study Type :||Observational|
|Estimated Enrollment :||125 participants|
|Official Title:||Blood Flow MRI for Monitoring of Glioma Angiogenesis|
|Study Start Date :||June 2006|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 31, 2021|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538264
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||David C Alsop, PhD||Beth Israel Deaconess Medical Center|